Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults).
Abouyannis M, FitzGerald R, Ngama M, Mwangudzah H, Nyambura YK, Ngome S, Riako D, Babu L, Lewa F, Else L, Dily Penchala S, Orindi B, Mumba N, Kalama B, Ndungu FM, Adetifa I, Khoo S, Lalloo DG, Casewell NR, Hamaluba M. Abouyannis M, et al. Among authors: mumba n. Wellcome Open Res. 2022 Mar 14;7:90. doi: 10.12688/wellcomeopenres.17682.1. eCollection 2022. Wellcome Open Res. 2022. PMID: 35372700 Free PMC article.
A global core outcome measurement set for snakebite clinical trials.
Abouyannis M, Esmail H, Hamaluba M, Ngama M, Mwangudzah H, Mumba N, Yeri BK, Mwalukore S, Alphan HJ, Aggarwal D, Alcoba G, Cammack N, Chippaux JP, Coldiron ME, Gutiérrez JM, Habib AG, Harrison RA, Isbister GK, Lavonas EJ, Martins D, Ribeiro I, Watson JA, Williams DJ, Casewell NR, Walker SA, Lalloo DG; Snakebite Global Core Outcome Set Study Group. Abouyannis M, et al. Among authors: mumba n. Lancet Glob Health. 2023 Feb;11(2):e296-e300. doi: 10.1016/S2214-109X(22)00479-X. Lancet Glob Health. 2023. PMID: 36669810 Free article. Review.
A network of empirical ethics teams embedded in research programmes across multiple sites: opportunities and challenges in contributing to COVID-19 research and responses.
Ngwenya N, Ilo Van Nuil J, Nyirenda D, Chambers M, Cheah PY, Seeley J, Chi P, Mafuleka L, Nkosi B, Kamuya D, Davies A, Schneiders ML, Mumba N, Dlamini S, Desmond N, Marsh V, Rippon D, Parker M, Molyneux S. Ngwenya N, et al. Among authors: mumba n. Wellcome Open Res. 2023 Jan 27;7:48. doi: 10.12688/wellcomeopenres.17548.2. eCollection 2022. Wellcome Open Res. 2023. PMID: 37636839 Free PMC article.
[A global core outcome measurement set for snakebite clinical trials].
Abouyannis M, Esmail H, Hamaluba M, Ngama M, Mwangudzah H, Mumba N, Yeri BK, Mwalukore S, Alphan HJ, Aggarwal D, Alcoba G, Cammack N, Chippaux JP, Coldiron ME, Gutiérrez JM, Habib AG, Harrison RA, Isbister GK, Lavonas EJ, Martins D, Ribeiro I, Watson JA, Williams DJ, Casewell NR, Walker SA, Lalloo DG. Abouyannis M, et al. Among authors: mumba n. Med Trop Sante Int. 2023 Sep 5;3(3):mtsi.v3i3.2023.421. doi: 10.48327/mtsi.v3i3.2023.421. eCollection 2023 Sep 30. Med Trop Sante Int. 2023. PMID: 38094484 Free PMC article. French.
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo MS, Dicko A, Tinto H, Ouédraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos Lopez F, Natama HM, Weston S, Chemba M, Compaore YD, Issiaka D, Salou D, Some AM, Omenda S, Lawrie A, Bejon P, Rao H, Chandramohan D, Roberts R, Bharati S, Stockdale L, Gairola S, Greenwood BM, Ewer KJ, Bradley J, Kulkarni PS, Shaligram U, Hill AVS; R21/Matrix-M Phase 3 Trial Group. Datoo MS, et al. Lancet. 2024 Feb 10;403(10426):533-544. doi: 10.1016/S0140-6736(23)02511-4. Epub 2024 Feb 1. Lancet. 2024. PMID: 38310910 Free article. Clinical Trial.
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M, Sang S, Orindi B, Njau I, Karanja H, Kamau N, Gitonga JN, Mugo D, Wright D, Nyagwange J, Kutima B, Omuoyo D, Mwatasa M, Ngetsa C, Agoti C, Cheruiyot S, Nyaguara A, Munene M, Mturi N, Oloo E, Ochola-Oyier L, Mumba N, Mauncho C, Namayi R, Davies A, Tsofa B, Nduati EW, Aliyan N, Kasera K, Etyang A, Boyd A, Hill A, Gilbert S, Douglas A, Pollard A, Bejon P, Lambe T, Warimwe G; COV004 Vaccine Trial Group. Hamaluba M, et al. Among authors: mumba n. Wellcome Open Res. 2023 Nov 27;8:182. doi: 10.12688/wellcomeopenres.19150.2. eCollection 2023. Wellcome Open Res. 2023. PMID: 38707489 Free PMC article.
41 results